Gilberto Baez Rios, MD
Cardiovascular Disease · Mayaguez, PRNPI 1487628210
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,700 of the $32,875 with a category attached, or 81.2%. Johnson & Johnson accounts for 90.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $14,528 and has fallen 97.7% since, to $329 in 2025. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $234.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$30K
- AstraZeneca$672
- Amgen$432
- Boehringer Ingelheim$421
- Boston Scientific$339
- Medtronic$312
- plus $812 from 12 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$26,70081%
- Travel & lodging$1,1784%
- Food & beverage$4,64914%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 63 | $29,886 |
| AstraZeneca | 19 | $672 |
| Amgen | 8 | $432 |
| Boehringer Ingelheim | 8 | $421 |
| Boston Scientific | 5 | $339 |
| Medtronic(2 entities) | 7 | $312 |
| PBG Puerto Rico LLC | 8 | $182 |
| E.r. Squibb & Sons, L.L.C. | 4 | $120 |
| Merck | 3 | $100 |
| Abbott | 1 | $86 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $66 |
| Novartis | 1 | $60 |
| Bayer Puerto Rico Inc. | 2 | $49 |
| Bayer | 2 | $46 |
| Pfizer | 1 | $30 |
| Edwards Lifesciences | 1 | $29 |
| Biotronik Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,875 in reported general payments places this provider in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 325 | $281,237 |
| FarxigaDapagliflozin Propanediol | 256 | $192,452 |
| EliquisApixaban | 67 | $54,311 |
| EntrestoSacubitril/Valsartan | 70 | $54,230 |
| JanuviaSitagliptin Phosphate | 18 | $21,399 |
| JardianceEmpagliflozin | 17 | $14,040 |
| Candesartan Cilexetil | 105 | $10,173 |
| Losartan Potassium | 742 | $7,336 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 224 | $7,129 |
| SynthroidLevothyroxine Sodium | 64 | $6,843 |
| Metoprolol Succinate | 484 | $6,101 |
| Rosuvastatin Calcium | 552 | $5,777 |
| Ranolazine ErRanolazine | 36 | $5,166 |
| Atorvastatin Calcium | 471 | $5,013 |
| Irbesartan | 167 | $4,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $29,886 | $281,237325 claims |
| AstraZenecaFarxiga | $672 | $192,452256 claims |
| PfizerEliquis | $30 | $54,31167 claims |
| NovartisEntresto | $60 | $54,23070 claims |
| MerckJanuvia | $100 | $21,39918 claims |
| Boehringer IngelheimJardiance | $421 | $14,04017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in Mayaguez
- Karen Rodriguez MaldonadoMayaguez$231K
- Carlos Rosario SepulvedaMayaguez$12K
- Jose NovoaBayamon$209K
- Manuel GuzmanSan Juan$203K
- Luis Rosado CarrilloGuaynabo$173K
- Jorge GonzalezCaguas$114K
- Luis GelyCaguas$89K
- Luis Renta RosaCarolina$83K
- Ramon PereaSan Juan$68K
- Denis Ruiz SerranoGuaynabo$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.